Bavarian Nordic's sales of rabies vaccines Rabipur/Rabavert and Encepur, the company's tick-borne encephalitis vaccine, could take center stage when the pharmaceutical company releases its financial report tomorrow, says the Danish bank Sydbank.
Moreover, investors can look forward to news about Bavarian's Covid-19 and RSV vaccines, the bank expects.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.